Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Prostate. Found 31 abstracts

no pagination
Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Practical radiation oncology. 2018 Jan;8(1):40-7.
Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CA, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys. 2018 Oct;102(2):287-95.   PMCID: PMC6248906
Ristau BT, Smaldone MC. Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: No. International braz j urol : official journal of the Brazilian Society of Urology. 2016 Sep;42(5):880-2.   PMCID: PMC5066883
Huang KT, Stoyanova R, Walker G, Sandler K, Studenski MT, Dogan N, Al-Saleem T, Buyyounouski MK, Horwitz EM, Pollack A. Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. Radiother Oncol. 2015 Apr;115(1):101-6.   PMCID: 4922137
Tong X, Chen XM, Li JS, Xu QQ, Lin MH, Chen LL, Price RA, Ma CM. Intrafractional prostate motion during external beam radiotherapy monitored by a real-time target localization system. J Appl Clin Med Phys. 2015 Mar 08;16(2):51-61.
Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. J Clin Oncol. 2014 Dec 20;32(36):4066-72.   PMCID: Pmc4265117
Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Sep;13(5):456-64.
Klayton TL, Ruth K, Horwitz EM, Uzzo RG, Kutikov A, Chen DY, Sobczak M, Buyyounouski MK. Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiotherapy and Oncology. 2011 Dec;101(3):508-12.   PMCID: PMC3225561
Buyyounouski MK. Androgen deprivation therapy in high-risk prostate cancer. Oncology (Williston Park). 2010 Aug;24(9):806, 809.   PMCID: Not NIH funded
Sharma NK, Cohen RJ, Eade TN, Buyyounouski MK, Uzzo RG, Li JS, Crawford K, Chen DY, McNeeley S, Horwitz EM. An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy. 2010 Apr;9(2):126-30.   PMCID: not NIH funded
Li JS, Jin L, Pollack A, Horwitz EM, Buyyounouski MK, Price RA, Ma CM. Gains from real-time tracking of prostate motion during external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Dec;75(5):1613-20.
Kaplan DJ, Crispen PL, Greenberg RE, Chen DY, Viterbo R, Buyyounouski MK, Horwitz EM, Uzzo RG. Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens. Urology. 2008 Sep;72(3):654-8.   PMCID: PMC2660570
Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. Journal of Urology. 2005 Jan;173(5):1456-62.
Badawi AF, Liu Y, Eldeen MB, Morrow W, Razak ZR, Maradeo M, Badr MZ. Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate. Carcinogenesis. 2004 Sep;25(9):1681-8.
Chen L, Price RA, Wang L, Li J, Qin L, McNeeley S, Ma CM, Freedman GM, Pollack A. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT. International Journal of Radiation Oncology, Biology, Physics. 2004 Oct;60(2):636-47.
Diefenbach MA, Butz BP. A Multimedia Interactive Education System for Prostate Cancer Patients: Development and Preliminary Evaluation. Journal of medical Internet research. 2004 Jan;6(1):[np].
Butts K, Daniel BL, Chen L, Bouley DM, Wansapura J, Maier SE, Dumoulin C, Watkins R. Diffusion-weighted MRI after cryosurgery of the canine prostate. Magnetic resonance imaging. J Magn Reson Imaging. 2003 Jan;17(1):131-5.
Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, Pollack A. Positive prostate biopsy laterality and implications for staging. Urology. 2003 Aug;62(2):298-303.
Chandra A, Dong L, Huang E, Kuban DA, O'Neill L, Rosen I, Pollack A. Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys. 2003 Jun;56(2):436-47.
D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A. Is intraoperative nomogram-based overplanning of prostate implants necessary?. Int J Radiat Oncol Biol Phys. 2003 Jun;56(2):462-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Prostate

Prostate Male Prostatic Neoplasms radiotherapy methods pathology Computer-Assisted Radiotherapy Planning Aged Human Middle Aged Conformal Radiotherapy Treatment Outcome Radiotherapy Dosage Movement Radiotherapy Prostate-Specific Antigen US Gov't Support-Non-PHS Prostatectomy diagnosis X-Ray Computed Tomography 80 and over Aged radiography Four-Dimensional Computed Tomography ultrasonography US Gov't Support-PHS instrumentation Prostatic neoplasms Neoplasm Staging Interventional Ultrasonography anatomy & histology Brachytherapy Dose Fractionation Biopsy therapeutic use Prostate cancer Retrospective Studies therapy Time Factors Rectum Tumor Burden blood Enzymologic Gene Expression Regulation Needle Biopsy conformality Kaplan-Meier Estimate EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) cancer Apoptosis 0 (Bax protein) EC 2-7-1-37 (Protein Kinase C) 0 (Proto-Oncogene Proteins c-bcl-2) Prostaglandin-Endoperoxide Synthase Physiologic Monitoring Proto-Oncogene Proteins diagnostic imaging phase-iii trial Diffusion Magnetic Resonance Imaging Biological Markers Cryosurgery 0 (Biological Markers) Adult Protein Kinase C Computer Systems Conformal Middle Age EC 1-14-99 (cyclooxygenase 2) external-beam radiation Health Education Rats radiation therapy surgery Multivariate Analysis Imaging Phantoms Computer Software prostate cancer Post-treatment Inbred F344 Rats Urethra EC 2-7-1 (protein kinase C alpha) Early Detection of Cancer Clinical Trials as Topic Aging Client Education Magnetic Resonance Imaging Proportional Hazards Models Tumor Biomarkers Dinoprostone Proto-Oncogene Proteins c-bcl-2 Intraoperative planning Follow-Up Studies reduction prostate specific antigen embolization dosimetry Intensity-Modulated Radiotherapy Prospective Studies Low-dose rate Radiation Oncology biosynthesis ra [Radiography] Feasibility Studies Isoenzymes men younger Adenocarcinoma 0 (Isoenzymes) ge [Genetics] statistics & numerical data competing group protocol 92-02 Prostate-specific antigen mt [Methods] Androgen Antagonists androgen deprivation ultrahypofractionation di [Diagnosis] Biochemical control Non-US Gov't Support chemically induced urine Quality of Life Linear Models Neoplasm Antigens 0 (Proto-Oncogene Proteins) implantation standards Cardiovascular Diseases Disease Susceptibility migration contraindications quality patient age Medical Oncology Rotation Risk Assessment Low-dose-rate brachytherapy Messenger) 0 (RNA Palpation Organ Size Failure patterns rt [Radiotherapy] en [Enzymology] Messenger RNA disease-free survival pa [Pathology] Age factors Iodine Radioisotopes Bladder 363-24-6 (Dinoprostone) postimplant trus images Combined Modality Therapy
Last updated on Friday, July 10, 2020